Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention

Rituximab (RTX) has become a standard therapy for certain B cell malignancies and autoimmune diseases. We report 2 RTX-treated patients who developed severe tick-borne encephalitis virus (TBEV) infection. The inability to generate new antibody responses renders RTX-treated patients susceptible to TB...

Descripción completa

Detalles Bibliográficos
Autores principales: Steininger, Philipp A, Bobinger, Tobias, Dietrich, Wenke, Lee, De-Hyung, Knott, Michael, Bogdan, Christian, Korn, Klaus, Lang, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
ID Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903409/
https://www.ncbi.nlm.nih.gov/pubmed/29670929
http://dx.doi.org/10.1093/ofid/ofx204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903409/
https://www.ncbi.nlm.nih.gov/pubmed/29670929
http://dx.doi.org/10.1093/ofid/ofx204

Ejemplares similares